Maria Rios

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. pmc Genetic variability of West Nile virus in US blood donors, 2002-2005
    Andriyan Grinev
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 14:436-44. 2008
  2. doi request reprint In vitro evaluation of the protective role of human antibodies to West Nile virus (WNV) produced during natural WNV infection
    M Rios
    Laboratory of Molecular Virology Division of Emerging Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    J Infect Dis 198:1300-8. 2008
  3. ncbi request reprint West Nile virus adheres to human red blood cells in whole blood
    Maria Rios
    Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Infect Dis 45:181-6. 2007
  4. ncbi request reprint Monocytes-macrophages are a potential target in human infection with West Nile virus through blood transfusion
    Maria Rios
    Laboratory of Molecular Virology LMV, Division of Emerging Transfusion Transmitted Diseases DETTD, Center for Biologics Evaluation and Research CBER, Food and Drug Administration FDA, Bethesda, MD 20892, USA
    Transfusion 46:659-67. 2006
  5. pmc Anti-West Nile virus activity of in vitro expanded human primary natural killer cells
    Mingjie Zhang
    Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20892, USA
    BMC Immunol 11:3. 2010
  6. pmc Phylogenetic analysis of dengue virus types 1 and 4 circulating in Puerto Rico and Key West, Florida, during 2010 epidemics
    Germán Añez
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Am J Trop Med Hyg 87:548-53. 2012
  7. pmc beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL
    Mingjie Zhang
    Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Retrovirology 5:82. 2008
  8. pmc Evolutionary dynamics of West Nile virus in the United States, 1999-2011: phylogeny, selection pressure and evolutionary time-scale analysis
    Germán Añez
    Laboratory of Emerging Pathogens, DETTD OBRR CBER, US Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Negl Trop Dis 7:e2245. 2013
  9. doi request reprint Application of a full-genome microarray-based assay for the study of genetic variability of West Nile virus
    Andriyan Grinev
    Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, US Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA
    J Virol Methods 183:219-23. 2012
  10. doi request reprint Microarray-based assay for the detection of genetic variations of structural genes of West Nile virus
    Andriyan Grinev
    Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Rockville, MD 20852, USA
    J Virol Methods 154:27-40. 2008

Collaborators

Detail Information

Publications19

  1. pmc Genetic variability of West Nile virus in US blood donors, 2002-2005
    Andriyan Grinev
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 14:436-44. 2008
    ..37%), suggesting absence of strong selective pressure and limited genetic evolution of WNV during that period. Nevertheless, WNV has continued to diverge from precursor isolates as geographic distribution of the virus has expanded...
  2. doi request reprint In vitro evaluation of the protective role of human antibodies to West Nile virus (WNV) produced during natural WNV infection
    M Rios
    Laboratory of Molecular Virology Division of Emerging Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    J Infect Dis 198:1300-8. 2008
    ..All but 1 documented WNV transmission by transfusion involved blood components negative for WNV antibodies, raising the question whether WNV antibody-positive blood components with low levels of WNV RNA are infectious...
  3. ncbi request reprint West Nile virus adheres to human red blood cells in whole blood
    Maria Rios
    Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Clin Infect Dis 45:181-6. 2007
    ..Conclusions. These observations reinforce the notion that extraction of viral RNA from whole blood could improve assay sensitivity for blood donor screening and further reduce the residual risk of WNV transmission through transfusion...
  4. ncbi request reprint Monocytes-macrophages are a potential target in human infection with West Nile virus through blood transfusion
    Maria Rios
    Laboratory of Molecular Virology LMV, Division of Emerging Transfusion Transmitted Diseases DETTD, Center for Biologics Evaluation and Research CBER, Food and Drug Administration FDA, Bethesda, MD 20892, USA
    Transfusion 46:659-67. 2006
    ..Whether primary monocyte-derived macrophages (MDMs) support WNV infection-replication and produce infectious virions, with an in vitro system, was investigated...
  5. pmc Anti-West Nile virus activity of in vitro expanded human primary natural killer cells
    Mingjie Zhang
    Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20892, USA
    BMC Immunol 11:3. 2010
    ..The expanded NK cells were tested for their ability to inhibit WNV infection in vitro...
  6. pmc Phylogenetic analysis of dengue virus types 1 and 4 circulating in Puerto Rico and Key West, Florida, during 2010 epidemics
    Germán Añez
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Am J Trop Med Hyg 87:548-53. 2012
    ..Introduction and circulation of novel DENV lineages in dengue-endemic regions have the potential to increase the severity of dengue cases...
  7. pmc beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL
    Mingjie Zhang
    Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Retrovirology 5:82. 2008
    ..Recent work suggests there are gender effects in HIV/AIDS progression. Here we ask whether the sex steroid hormone beta-estradiol affects the replication of HIV-1 or the efficacy of a common anti-retroviral drug, Stavudine (D4T)...
  8. pmc Evolutionary dynamics of West Nile virus in the United States, 1999-2011: phylogeny, selection pressure and evolutionary time-scale analysis
    Germán Añez
    Laboratory of Emerging Pathogens, DETTD OBRR CBER, US Food and Drug Administration, Bethesda, Maryland, USA
    PLoS Negl Trop Dis 7:e2245. 2013
    ....
  9. doi request reprint Application of a full-genome microarray-based assay for the study of genetic variability of West Nile virus
    Andriyan Grinev
    Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, US Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA
    J Virol Methods 183:219-23. 2012
    ..S. epidemics. The developed microarray system can potentially serve as a high throughput, rapid, and effective approach for the detection of circulating WNV genetic variants...
  10. doi request reprint Microarray-based assay for the detection of genetic variations of structural genes of West Nile virus
    Andriyan Grinev
    Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Rockville, MD 20852, USA
    J Virol Methods 154:27-40. 2008
    ....
  11. ncbi request reprint Evaluation of FDA licensed HIV assays using plasma from Cameroonian blood donors
    Sherwin Lee
    Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, U S Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Med Virol 78:S22-3. 2006
    ..In addition, some nucleic acid tests (NAT) assays were not able to detect a few serologic reactive samples and all new variants including some CRF02_AG variants...
  12. doi request reprint Polymerase chain reaction-based tests for pan-species and species-specific detection of human Plasmodium parasites
    Babita Mahajan
    Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20852, USA
    Transfusion 52:1949-56. 2012
    ....
  13. ncbi request reprint Human T lymphotropic virus types I and II western blot seroindeterminate status and its association with exposure to prototype HTLV-I
    Karen Yao
    Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 193:427-37. 2006
    ..Our findings warrant further investigation of the possible clinical outcomes associated with WB seroindeterminate status...
  14. pmc Dengue in the United States of america: a worsening scenario?
    Germán Añez
    Laboratory of Emerging Pathogens, DETTD OBRR CBER, U S Food and Drug Administration, Bethesda, MD 20892, USA
    Biomed Res Int 2013:678645. 2013
    ....
  15. pmc Circulation of different lineages of dengue virus type 2 in Central America, their evolutionary time-scale and selection pressure analysis
    Germán Añez
    Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland, United States of America
    PLoS ONE 6:e27459. 2011
    ..Some of these identified codons are novel findings, described for the first time for any of the DENV-2 genotypes...
  16. ncbi request reprint Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer
    Claire Julian-Reynier
    Institut National de la Sante et de la Recherche Medicale, U379, Epidemiology and Social Sciences Unit, Marseille, France
    J Clin Oncol 25:3038-44. 2007
    ..Cancer patients participating in randomized controlled trials (RCTs) have not been found to have better clinical outcomes than other patients. Our objective was to assess the impact of RCTs on patients' satisfaction with care...
  17. ncbi request reprint Evidence that Hy- RBCs express weak Joa antigen
    Terry L Scofield
    American Red Cross North Central Blood Services, St Paul, Minnesota 55107, USA
    Transfusion 44:170-2. 2004
    ..Historically, anti-Joa has not reacted with RBCs with either phenotype. This report describes a case of an anti-Joa that shows Hy- RBCs express some Joa antigen, albeit weakly...
  18. ncbi request reprint Blood group genotyping facilitates transfusion of beta-thalassemia patients
    Lilian Castilho
    Hemocentro Unicamp, Campinas, SP, Brasil
    J Clin Lab Anal 16:216-20. 2002
    ....
  19. ncbi request reprint DNA-based typing of blood groups for the management of multiply-transfused sickle cell disease patients
    Lilian Castilho
    Hematology and Hemotherapy Center, State University of Campinas UNICAMP, Campinas, SP, Brazil
    Transfusion 42:232-8. 2002
    ..The usefulness of DNA genotyping for RBC antigens as a tool for the management of multiply-transfused patients with sickle cell disease (SCD) to overcome the limitations of hemagglutination assays was evaluated...